Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Entrada Therapeutics (TRDA) Invested Capital (2022 - 2025)

Historic Invested Capital for Entrada Therapeutics (TRDA) over the last 4 years, with Q3 2025 value amounting to $340.7 million.

  • Entrada Therapeutics' Invested Capital fell 1934.7% to $340.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $340.7 million, marking a year-over-year decrease of 1934.7%. This contributed to the annual value of $428.7 million for FY2024, which is 7687.65% up from last year.
  • As of Q3 2025, Entrada Therapeutics' Invested Capital stood at $340.7 million, which was down 1934.7% from $379.5 million recorded in Q2 2025.
  • In the past 5 years, Entrada Therapeutics' Invested Capital registered a high of $429.9 million during Q2 2024, and its lowest value of $206.9 million during Q2 2023.
  • For the 4-year period, Entrada Therapeutics' Invested Capital averaged around $306.2 million, with its median value being $269.4 million (2024).
  • Its Invested Capital has fluctuated over the past 5 years, first soared by 10778.56% in 2024, then plummeted by 1934.7% in 2025.
  • Over the past 4 years, Entrada Therapeutics' Invested Capital (Quarter) stood at $212.6 million in 2022, then rose by 14.02% to $242.4 million in 2023, then skyrocketed by 76.88% to $428.7 million in 2024, then dropped by 20.52% to $340.7 million in 2025.
  • Its last three reported values are $340.7 million in Q3 2025, $379.5 million for Q2 2025, and $417.3 million during Q1 2025.